ArticleEuropean journal of haematology2025

Efficacy and Safety of Frontline Single-Agent Rituximab in Extranodal Marginal Zone Lymphoma.

Camilla Mazzoni et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.